摘要目的 探讨高压氧(hyperbaric oxygen,HBO)辅助治疗对胃癌腹膜转移患者的临床效果及生活质量的影响.方法 回顾性分析2014年8月至2016年8月衡水市人民医院胃肠外科收治的88例胃癌腹膜转移患者,按患者的治疗方式分为观察组(n=39)和对照组(n=49).对照组采用常规化疗,观察组在对照组治疗的基础上联合HBO辅助治疗.治疗2个疗程后,比较2组患者的近期疗效及急性、亚急性毒性反应,并采用QLQ-C30癌症患者生活质量量表评估患者的生活质量;对患者随访1年,比较2组的疾病进展时间及生存时间.结果 观察组和对照组患者的客观有效率(ORR)分别是53.85％和46.94％(χ2=0.414,P=0.520).观察组患者消化道和血液毒性反应评分均明显低于对照组[(1.08±0.26)vs.(3.26±0.62)分,(1.01±0.22)vs.(1.67±0.41)分,均P<0.05].观察组和对照组的中位疾病进展时间分别是6.1个月和3.0个月,中位生存时间分别是8.9个月和5.1个月,观察组均高于对照组(P<0.05).观察组患者的生活质量综合评分及躯体功能评分均高于对照组(P<0.05).结论HBO辅助治疗胃癌腹膜转移患者具有较好的近期疗效,能够延缓疾病进展,提高患者的生活质量,且不良反应相对较小.

abstractsObjective To explore the clinical effects of adjuvant hyperbaric oxygen ( HBO) therapy on peritoneal metastasis of gastric cancer. Methods A retrospective analysis was made on the 88 patients with peritoneal metastasis of gastric cancer admitted to the hospital from August 2014 to August 2016. The patients were divided into the observation group ( n =39 ) and the control group ( n =49 ) by different treatment methods. The control group was treated with chemotherapy, while the observation group received adjuvant HBO therapy in addition to the treatment received by the control group. After 2 courses of treatment, the short-term efficacy and acute and sub-acute toxicity were compared between the patients of the 2 groups, and the life quality of the patients was evaluated by using QLQ-C30. One-year medical follow up was made, and disease progression and survival time were compared between the patients of the 2 groups. Results The objective response rate (ORR) of the observation group and the control group were 53. 85％ and 46. 94％, respectively. There was no statistical difference, when comparison was made between the 2 groups(χ2 =0. 414, P=0. 520). The digestive tract and blood toxicity scores of the observation group were (1. 08 ± 0. 26)and (1. 01 ± 0. 22) respectively, which were significantly lower than (3. 26 ± 0. 62) and (1. 67 ± 0. 41) of the control group (P<0. 05). The median disease progression time of the observation group and the control group was respectively 6 months and 3 months, and the median survival time was respectively 8. 9 months and 5. 1&nbsp;months, with the observation group all being superior to those of the control group ( P < 0. 05 ). The comprehensive scores of the life quality and physical function in the observation group were higher than those in the control group (P<0. 05). Conclusion HBO adjuvant therapy for gastric cancer patients with peritoneal metastasis has good short-term efficacy, and could slow disease progress, improve their life quality, and more importantly showed less adverse reactions.